Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Kamada Licenses Alvotech Biosimilars In Israel

First Launch, Teriparatide, Is Slated For 2022

Executive Summary

Israel’s Kamada has struck a licensing deal with Alvotech that gives it rights to several of the firm’s biosimilars in its domestic market. The first launch, of the teriparatide biosimilar co-developed with Pfenex, is planned for 2022.

You may also be interested in...



Israel’s Kamada Eyes $40m Sales As Alvotech Alliance Increases

Following on from its initial 2019 alliance, Israel’s Kamada has added a further two biosimilar products to its local distribution agreement with Alvotech. The firm’s CEO discussed its planned foray into the biosimilar space as part of a letter to shareholders.

Kamada Plans Three More Biosimilar Launches In Israel

Israeli firm Kamada has entered into two agreements for commercialization of three biosimilars in Israel. The company expects to launch the products between 2022 and 2024. 

Teva Takes Tuznue Trastuzumab Biosimilar In Israel From Prestige

Prestige BioPharma is continuing to put pen to paper on deals to supply and sell its HD201 biosimilar trastuzumab candidate, this time partnering with Israeli giant Teva for local commercialization rights.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

GB149412

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel